161 patents currently held
5 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
48 more records may belong here and await a decision; they are not counted.
The next term ends in Dec 2026. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
67
Ending by 2030
Dec 2026
Next term end
78
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Sep 2031 · High confidence
Also notable
Ends no later than Nov 2027 · Medium confidence
Also notable
Ends Jun 2030 · High confidence
Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses
US 7,449,458
The most cited patent in this portfolio, cited by 200 later US patents, top 5% of utility patents granted in 2008 in our data. Protection runs to 2031.
Cycloalkyl Substituted Pyrimidinediamine Compounds and Their Uses
US 7,858,633
Cited by 146 later US patents, top 5% of utility patents granted in 2010 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Compositions and Methods for Inhibition of the Jak Pathway
US 8,324,200
Cited by 43 later US patents, top 25% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2030.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 3 fees due Nov 19 to 26, 2026 · next Nov 19
- 5 fees due Dec 4 to 23, 2026 · next Dec 4
- 2 fees due Jan 14 to 21, 2027 · next Jan 14
- 5 fees due Feb 4 to 18, 2027 · next Feb 4
- 3 fees due Mar 17 to 29, 2027 · next Mar 17
- 3 fees due Apr 8 to 27, 2027 · next Apr 8
- 4 fees due May 3 to 19, 2027 · next May 3
- 1 fee due Jun 8, 2027The maintenance fee for Bridged Bicyclic Heteroaryl Substituted Triazoles Useful as Axl Inhibitors (US 9,206,161) comes due Jun 8, 2027. Unpaid by Dec 8, 2027, it lapses early.
- 1 fee due Jul 16, 2027The maintenance fee for Ret Inhibitor for Use in Treating Cancer Having a Ret Alteration (US 11,872,192) comes due Jul 16, 2027. Unpaid by Jan 18, 2028, it lapses early.
- 4 fees due Aug 2 to 11, 2027 · next Aug 2
- 4 fees due Sep 5 to 26, 2027 · next Sep 5
- 2 fees due Oct 23 to 26, 2027 · next Oct 23
- 1 fee due Nov 12, 2027The maintenance fee for Nrf2 Activating Compounds and Uses Thereof (US 10,647,697) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.
Recent changes
- Oct 13Assignment recorded on 1 record: Chao, Mwe Mwe and 1 other to Rigel Pharmaceuticals, Inc. Recorded Oct 13, 2026, executed Jul 20, 2026. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76360, frame 773.
- 1 of the patents on this record was granted since Aug 17, 2026
- 4 terms have ended since Aug 17, 2026
What they patent
The 5 largest of its 78 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | 34 in force | to Nov 2043 |
| Amide Compounds and Method for Making and Using | 4 in force | to Oct 2037 |
| Irak Inhibitors and Method for Making and Using | 4 in force | to Oct 2037 |
| Benzazole Compounds and Methods for Making and Using the Compounds | 4 in force | to Oct 2036 |
| Compositions and Methods for Inhibition of the Jak Pathway | 4 in force | to Jul 2031 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,566,732 | Rhodanine Compositions for Use as Antiviral Agents In force · High confidence | In force | High confidence | |
| US 7,459,301 | Stereoisomerically Enriched N-Protected Beta-Lactams Using Candida Antarctica In force · High confidence | In force | High confidence | |
| US 7,514,434 | Heterocyclic Compounds Having an Oxadiazole Moiety and Hydro Isomers Thereof In force · High confidence | In force | High confidence | |
| US 7,521,560 | 2-Substituted Quinoline Compounds and Their Uses In force · High confidence | In force | High confidence | |
| US 7,511,137 | Stereoisomers and Stereoisomeric Mixtures of 1-(2,4-Pyrimidinediamino)-2-Cyclopentanecarboxamide Synthetic Intermediates In force · High confidence | In force | High confidence | |
| US 7,872,096 | Methods for Cyclizing Synthetic Polymers In force · High confidence | In force | High confidence | |
| US 7,659,280 | 2,4-Pyrimidinediamine Compounds for Treating or Preventing Autoimmune Diseases In force · High confidence | In force | High confidence | |
| US 7,915,273 | Compositions and Methods for Inhibition of the Jak Pathway In force · Medium confidence | In force | Medium confidence | |
| US 8,053,434 | Kinase Inhibitors and Their Uses In force · High confidence | In force | High confidence | |
| US 7,601,713 | Kinase Inhibitors and Their Uses In force · High confidence | In force | High confidence |
Also on record, not counted in the 161: 5 patents in force now held by others · 265 patents ended · 19 applications pending · 100 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.